Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon DPP‑4 inhibitors Prior Auth Coverage | …
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Dipeptidyl peptidase 4 (DPP-4) inhibitors prior authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization for DPP-4 inhibitor products (alogliptin and combination products) for CareOregon members, specifying approval length and clinical step criteria for coverage.

    Policy Summary
    Payercareoregon
    PolicyDipeptidyl peptidase 4 (DPP-4) inhibitors prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trials or contraindications/intolerance to metformin and trial and failure of pioglitazone (sulfonylureas accepted as alternative) to support approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    LifetimeAuthorization length
    3Criteria count
    7/1/2026Effective date (M/D/Y)

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Authorization: Requested drug is FDA-approved for the condition being treated; trial and failure, contraindication, or intolerance to metformin; trial and failure of pioglitazone (sulfonylureas accepted as an alternative to pioglitazone but not required).

    Approval length: Lifetime (through 12/31/2039)

    None explicitly stated in the source document.

    Use this guideline to determine that a request is not medically necessary when the requested drug is not FDA‑approved for the condition being treated or when the required step‑therapy conditions (trial and failure, documented contraindication, or intolerance to metformin, and trial and failure of pioglitazone or an accepted sulfonylurea) are not satisfied.

    Initial Therapy

    Initial Therapy

    Initial authorization requires meeting ALL of the following criteria:

    Policy Summary
    Payercareoregon
    PolicyDipeptidyl peptidase 4 (DPP-4) inhibitors prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trials or contraindications/intolerance to metformin and trial and failure of pioglitazone (sulfonylureas accepted as alternative) to support approval.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyProvider Actions & RequirementsStep Therapy DetailsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial drug criteria: Requested drug is FDA-approved for the condition being treated.
    Metformin trial requirement: Trial and failure, documented contraindication, or intolerance to metformin.

    Document reason for failure/intolerance/contraindication; clinical records required.

    Second-line agent requirement: Trial and failure of pioglitazone (sulfonylureas are accepted as an alternative to pioglitazone but are not required).

    Provider Actions & Requirements

    Prior Authorization

    Prior authorization required; approval length lifetime (through 12/31/2039)

    Prior authorization is required for alogliptin and the combination products alogliptin/metformin and alogliptin/pioglitazone. When the coverage criteria are met, approval length is lifetime (through 12/31/2039).

    Step Therapy

    Step therapy: metformin then pioglitazone (sulfonylurea alternative allowed)

    Step therapy must be documented before approval: the member must have trialed and failed, or have a contraindication or intolerance to, metformin; and must have trialed and failed pioglitazone. The policy notes that sulfonylureas are accepted as an alternative to pioglitazone but are not required.

    • Trial and failure, contraindication, or intolerance to metformin
    • Trial and failure of pioglitazone
    • Sulfonylureas accepted as an alternative to pioglitazone (not required)
    Documentation Required

    Required documentation: FDA approval and prior trials (metformin, pioglitazone/sulfonylurea)

    Document that the requested drug is FDA‑approved for the condition being treated and provide records of prior trials with metformin and with pioglitazone (or a sulfonylurea when accepted), including reasons for failure, intolerance, or contraindication.

    • Evidence of FDA approval for the indication
    • Clinical notes or medication history showing trial(s) of metformin and outcome
    • Clinical notes or medication history showing trial(s) of pioglitazone or accepted sulfonylurea and outcome, or documentation of contraindication/intolerance
    Denial Risk

    Denial triggers: lack of FDA approval or unmet step‑therapy

    Requests may be denied if the requested drug is not FDA‑approved for the condition being treated or if step‑therapy requirements (trial and failure or documented contraindication/intolerance to metformin and trial and failure of pioglitazone or accepted sulfonylurea) are not met.

    Step Therapy Details

    StepRequirement
    1
    Requested drug is FDA-approved for the condition being treated; must document FDA-approval for the indication.
    2
    Trial and failure, documented contraindication, or intolerance to metformin must be provided.
    3
    Trial and failure of pioglitazone (sulfonylureas are accepted as an alternative to pioglitazone but are not required).
    Step therapy (inv-09)
    DefinitionStep therapy: requirement that the member has trialed and failed (or has a documented contraindication or intolerance to) specified medications prior to approval of the requested DPP-4 inhibitor.
    Required prior agent (first step)Metformin — trial and failure, documented intolerance, or contraindication required.
    Required prior agent (second step)Pioglitazone — trial and failure required; sulfonylureas are accepted as an alternative to pioglitazone but are not required.
    Documentation neededClinical documentation must show trials (or contraindication/intolerance) and reasons for failure for the agents tried.
    ApplicabilityApplies to alogliptin and alogliptin combination products (alogliptin/metformin; alogliptin/pioglitazone) subject to prior authorization.

    Background

    Dipeptidyl peptidase‑4 (DPP‑4) inhibitors such as alogliptin are oral antihyperglycemic agents indicated for the treatment of type 2 diabetes. They act by inhibiting the DPP‑4 enzyme, which increases endogenous incretin hormones and helps regulate glucose. Combination products with metformin or pioglitazone combine complementary mechanisms to improve glycemic control. Prior authorization is used to ensure use after trials of first‑line therapy (for example, metformin) and specified second‑line agents (pioglitazone or accepted sulfonylureas) and to align approvals with the documented approval length: Lifetime (through 12/31/2039) when criteria are met.